Medical Experiment Center, Lanzhou Military Command General Hospital of the People's Liberation Army; Key Laboratory of Stem Cell and Gene Medicine of Gansu Province, Lanzhou, Gansu 730050, China.
Chin Med J (Engl). 2010 Sep;123(17):2454-60.
To review the effect of endothelial progenitor cells in neovascularization as well as their application to the therapy of tumors.
The data used in this review were mainly from PubMed for relevant English language articles published from 1997 to 2009. The search term was "endothelial progenitor cells".
Articles regarding the role of endothelial progenitor cells in neovascularization and their application to the therapy of tumors were selected.
Endothelial progenitor cells isolated from bone marrow, umbilical cord blood and peripheral blood can proliferate, mobilize and differentiate into mature endothelial cells. Experiments suggest endothelial progenitor cells take part in forming the tumor vascular through a variety of mechanisms related to vascular endothelial growth factor, matrix metalloproteinases, chemokine stromal cell-derived factor 1 and its receptor C-X-C receptor-4, erythropoietin, Notch signal pathway and so on. Evidence demonstrates that the number and function change of endothelial progenitor cells in peripheral blood can be used as a biomarker of the response of cancer patients to anti-tumor therapy and predict the prognosis and recurrence. In addition, irradiation temporarily increased endothelial cells number and decreased the endothelial progenitor cell counts in animal models. Meanwhile, in preclinical experiments, therapeutic gene-modified endothelial progenitor cells have been approved to attenuate tumor growth and offer a novel strategy for cell therapy and gene therapy of cancer.
Endothelial progenitor cells play a particular role in neovascularization and have attractively potential prognostic and therapeutic applications to malignant tumors. However, a series of problems, such as the definitive biomarkers of endothelial progenitor cells, their interrelationship with radiotherapy and their application in cell therapy and gene therapy of tumors, need further investigation.
综述内皮祖细胞在血管新生中的作用及其在肿瘤治疗中的应用。
检索 1997 年至 2009 年期间 Pubmed 上发表的有关内皮祖细胞在血管新生中作用及其在肿瘤治疗中应用的英文文献，检索词“endothelial progenitor cells”。
选择内皮祖细胞在血管新生中作用及其在肿瘤治疗中应用的相关文献。
从骨髓、脐血和外周血中分离出的内皮祖细胞可以增殖、动员并分化为成熟的内皮细胞。实验表明，内皮祖细胞通过与血管内皮生长因子、基质金属蛋白酶、趋化因子基质细胞衍生因子 1 及其受体 C-X-C 受体-4、促红细胞生成素、Notch 信号通路等多种机制参与肿瘤血管的形成。有证据表明，外周血中内皮祖细胞数量和功能的变化可作为癌症患者对抗肿瘤治疗反应的生物标志物，并预测预后和复发。此外，动物模型中照射可暂时增加内皮细胞数量，减少内皮祖细胞计数。同时，在临床前实验中，经治疗基因修饰的内皮祖细胞已被证实可减轻肿瘤生长，为癌症的细胞治疗和基因治疗提供了一种新策略。
内皮祖细胞在血管新生中发挥着特殊的作用，对恶性肿瘤具有潜在的预后和治疗应用价值。然而，内皮祖细胞的确切生物标志物、与放疗的相互关系及其在肿瘤细胞治疗和基因治疗中的应用等一系列问题仍需进一步研究。
